Skip to main content

Table 2 Summary of prevalence estimates for airflow obstruction, restriction, and spirometric SAO in the study population

From: The association of spirometric small airways obstruction with respiratory symptoms, cardiometabolic diseases, and quality of life: results from the Burden of Obstructive Lung Disease (BOLD) study

BOLD Centre

n

Airflow obstruction

n (%)

Restriction n (%)

Spirometric SAO

(FEV3/FVC)

n (%)

Isolated spirometric SAO

(FEV3/FVC)

n (%)

Spirometric SAO

(FEF25-75)

n (%)

Isolated spirometric

SAO

(FEF25-75)

n (%)

Albania (Tirana)

832

82 (10%)

123 (15%)

85 (10%)

22 (3%)

69 (8%)

22 (3%)

Algeria (Annaba)

802

85 (11%)

219 (27%)

75 (9%)

21 (3%)

103 (13%)

54 (7%)

Australia (Sydney)

387

58 (15%)

47 (12%)

72 (19%)

25 (7%)

43 (11%)

11 (3%)

Austria (Salzburg)

887

222 (25%)

74 (8%)

271 (31%)

114 (13%)

138 (16%)

25 (3%)

Benin (Sémé-Kpodji)

488

55 (11%)

385 (79%)

68 (14%)

36 (7%)

147 (30%)

110 (23%)

Cameroon (Limbe)

249

14 (6%)

151 (61%)

16 (7%)

7 (3%)

33 (13%)

23 (9%)

Canada (Vancouver)

594

105 (18%)

43 (7%)

135 (23%)

59 (10%)

69 (12%)

17 (3%)

China (Guangzhou)

295

33 (11%)

84 (29%)

37 (13%)

17 (6%)

54 (18%)

31 (11%)

England (London)

539

119 (22%)

83 (15%)

163 (30%)

70 (13%)

99 (18%)

31 (6%)

Estonia (Tartu)

545

69 (13%)

45 (8%)

83 (15%)

39 (7%)

29 (5%)

8 (1%)

Germany (Hannover)

414

55 (13%)

22 (5%)

53 (13%)

19 (5%)

36 (9%)

10 (2%)

Iceland (Reykjavik)

552

116 (21%)

69 (13%)

158 (29%)

63 (12%)

94 (17%)

25 (5%)

India (Mumbai)

315

26 (8%)

205 (65%)

27 (9%)

9 (3%)

68 (22%)

48 (15%)

India (Mysore)

531

49 (9%)

412 (78%)

55 (10%)

24 (5%)

176 (33%)

140 (26%)

India (Pune)

732

65 (9%)

474 (65%)

81 (11%)

36 (5%)

173 (24%)

130 (18%)

India (Kashmir)

677

144 (21%)

190 (28%)

156 (23%)

45 (7%)

179 (26%)

73 (11%)

Jamaica

459

45 (10%)

253 (55%)

84 (18%)

48 (10%)

87 (19%)

53 (12%)

Kyrgyzstan (Chui)

738

141 (19%)

81 (11%)

157 (215)

35 (5%)

137 (19%)

25 (3%)

Kyrgyzstan (Naryn)

755

84 (11%)

77 (10%)

124 (16%)

58 (8%)

108 (14%)

51 (7%)

Malawi (Blantyre)

331

33 (10%)

146 (44%)

58 (18%)

31 (10%)

82 (25%)

57 (17%)

Malawi (Chikwawa)

366

66 (18%)

135 (37%)

79 (22%)

30 (8%)

108 (30%)

64 (18%)

Malaysia (Penang)

616

25 (4%)

357 (58%)

38 (6%)

21 (3%)

78 (13%)

59 (10%)

Morocco (Fes)

429

37 (95)

80 (19%)

48 (11%)

15 (3%)

58 (14%)

31 (7%)

Netherlands (Maastricht)

538

124 (23%)

51 (9%)

151 (28%)

55 (10%)

95 (18%)

18 (3%)

Nigeria (Ife)

793

98 (12%)

568 (72%)

152 (19%)

76 (10%)

216 (27%)

149 (19%)

Norway (Bergen)

447

82 (18%)

39 (9%)

115 (265)

60 (14%)

66 (15%)

21 (5%)

Pakistan (Karachi)

311

38 (12%)

238 (77%)

49 (16%)

23 (7%)

86 (28%)

57 (18%)

Philippines (Manila)

651

98 (15%)

404 (62%)

89 (14%)

27 (4%)

154 (24%)

90 (14%)

Philippines (Nampicuan-Talugtug)

638

126 (20%)

366 (57%)

127 (20%)

40 (6%)

191 (30%)

112 (18%)

Poland (Krakow)

336

64 (19%)

34 (10%)

81 (24%)

33 (10%)

62 (19%)

20 (6%)

Portugal (Lisbon)

548

57 (10%)

52 (10%)

90 (165)

41 (7%)

54 (10%)

16 (3%)

Saudi Arabia (Riyadh)

576

31 (5%)

293 (51%)

29 (5%)

7 (1%)

63 (11%)

34 (6%)

South Africa (Uitsig and Ravensmead)

505

116 (23%)

232 (46%)

132 (26%)

46 (9%)

159 (31%)

79 (16%)

Sri Lanka (Colombo)

718

77 (11%)

602 (84%)

65 (9%)

12 (25)

200 (28%)

146 (20%)

Sudan (Gezeira)

277

20 (7%)

153 (55%)

30 (11%)

13 (5%)

38 (14%)

21 (8%)

Sudan (Khartoum)

367

39 (11%)

255 (70%)

56 (15%)

25 (7%)

76 (21%)

50 (14%)

Sweden (Uppsala)

393

56 (14%)

30 (8%)

56 (14%)

19 (5%)

31 (8%)

11 (3%)

Trinidad & Tobago (Port of Spain)

815

59 (7%)

606 (74%)

112 (14%)

72 (9%)

167 (21%)

121 (15%)

Tunisia (Sousse)

422

29 (7%)

98 (23%)

34 (8%)

16 (4%)

44 (10%)

22 (5%)

Turkey (Adana)

414

82 (20%)

56 (14%)

114 (28%)

53 (13%)

89 (22%)

33 (8%)

USA (Lexington)

312

51 (17%)

72 (23%)

55 (18%)

20 (6%)

69 (22%)

32 (10%)

  1. Spirometric SAO: small airways obstruction—Pre-bronchodilator FEF25-75 or FEV3/FVC less than the lower limit of normal (LLN). Isolated spirometric SAO: Pre-bronchodilator FEF25-75 or FEV3/FVC less than the lower limit of normal with FEV1/FVC ≥ LLN. AO: airflow obstruction—pre-bronchodilator FEV1/FVC < LLN. Restriction: Post-bronchodilator FVC < LLN. LLN calculated using spirometry reference equations taken from the NHANES III study population. FVC: Forced vital capacity. FEF25-75: Mean forced expiratory flow rate between 25 and 75% of the FVC. FEV3/FVC: Forced expiratory volume in 3 s as a ratio of the FVC. FEV1/FVC: Forced expiratory volume in 1 s as a ratio of the FVC